Fanconi renotubular syndrome 4 with HNF4A-MODY: A Patient Guide
At a Glance
FRTS4 with HNF4A-MODY is a rare HNF4A-related condition that can shift from newborn low blood sugar to childhood kidney and bone problems and later diabetes. Kidney, hormone, and genetics specialists coordinate monitoring as symptoms change.
Fanconi Renotubular Syndrome 4 with Maturity-Onset Diabetes of the Young (FRTS4 with MODY1) is an exceptionally rare genetic condition that affects the body’s internal “sorting” and “fuel” systems. At its core, this condition is caused by a change in the HNF4A gene, which serves as a master instruction manual for the development of cells in the kidneys and the pancreas [1]. Because this single gene helps manage how the kidneys recycle nutrients and how the pancreas releases insulin, a variation in its code can lead to a sequence of different health challenges that emerge at different stages of life.
What is Known and What Remains Uncertain
Because this condition is so rare, much of the medical evidence about FRTS4 comes from a single international study of just 25 patients, most of whom carried one specific genetic variant (p.Arg85Trp) [1]. While that study identified a common sequence of symptoms, not every person with an HNF4A variant will experience every phase, and the severity of kidney and pancreas issues can vary widely from person to person.
The condition is often described as “multi-phasic” because its symptoms change as a person grows. In the earliest phase, some infants are born with a high birth weight and experience dangerously low blood sugar, known as hyperinsulinemic hypoglycemia, because their pancreas produces too much insulin [2]. As this newborn phase resolves, the focus typically shifts to the kidneys in early childhood. During this second phase, the kidneys develop Fanconi syndrome, where they fail to reclaim vital minerals, sugar, and proteins from the urine. This “leaking” can lead to softened bones (rickets) and a gradual, progressive decline in overall kidney function over many years [1].
As patients reach adolescence or early adulthood, the pancreas often enters a third phase where it begins to produce too little insulin, rather than too much. This leads to a specific form of diabetes known as HNF4A-MODY (MODY1) [3]. Unlike more common forms of diabetes, MODY1 is typically not an autoimmune disease; instead, it is a direct result of the pancreatic cells struggling to release insulin correctly. Understanding this progression is vital because the treatments used for this specific type of diabetes often differ from those used for more common types, frequently responding well to specific oral medications [4].
Living with this condition requires a proactive, “whole-body” approach to medical care. Because the kidneys and pancreas are so closely linked by this genetic change, the most effective care happens when kidney specialists (nephrologists) and hormone specialists (endocrinologists) work together to monitor bone health, kidney filtration, and blood sugar levels. While the rarity of the diagnosis can feel isolating, understanding the underlying genetic cause empowers families to stay ahead of each phase, ensuring that growth, bone strength, and metabolic health are supported throughout a lifetime [5].
In this guide
6 chapters
Understanding Fanconi Renotubular Syndrome 4 with MODY
Learn how Fanconi renotubular syndrome 4 affects newborn blood sugar, childhood kidney function, and later HNF4A-MODY, including care needs and monitoring.
Kidney Health: Fanconi Syndrome and Progressive Decline
Learn how FRTS4, an HNF4A-related kidney disorder, causes Fanconi syndrome, bone and growth problems, chronic kidney disease, and urgent warning signs.
The Pancreas: From Low Blood Sugar to HNF4A-MODY
Learn how Fanconi renotubular syndrome 4 affects the pancreas, from newborn low blood sugar to HNF4A-MODY, diabetes screening, treatment, and long-term care.
Confirming the Diagnosis: Genetics and Reports
Learn how genetic testing confirms Fanconi renotubular syndrome 4, including HNF4A variants, inheritance, VUS results, and key details on a genetic report.
Standard Care: Managing Kidneys and Blood Sugar
Learn how Fanconi renotubular syndrome 4 is managed, including kidney supplements, rickets prevention, HNF4A-MODY treatment, and when insulin may be needed.
Long-Term Health and Pregnancy Planning
Learn how Fanconi renotubular syndrome 4 and HNF4A-MODY affect kidney monitoring, pregnancy medication planning, fetal growth, and newborn glucose safety.
Common questions in this guide
What causes Fanconi renotubular syndrome 4 with HNF4A-MODY?
What health problems can appear at different ages with FRTS4?
How is HNF4A-MODY different from more common types of diabetes?
Which specialists should care for someone with FRTS4?
What should be monitored over time with FRTS4 and HNF4A-MODY?
Does the p.Arg85Trp variant confirm the diagnosis?
Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (5)
- 1
Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.
Emma F, Böckenhauer D, Mallett AJ, et al.
Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.
PMID: 42440446 - 2
A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family.
Chandran S, Rajadurai VS, Hoi WH, et al.
Frontiers in pediatrics 2020; (8()):320 doi:10.3389/fped.2020.00320.
PMID: 32670997 - 3
Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas.
Sheppard SE, Barrett B, Muraresku C, et al.
American journal of medical genetics. Part A 2021; (185(2)):566-570 doi:10.1002/ajmg.a.61978.
PMID: 33251707 - 4
Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy.
Gulisano C, Aloi C, Salina A, et al.
Frontiers in medicine 2025; (12()):1590935 doi:10.3389/fmed.2025.1590935.
PMID: 40486195 - 5
Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).
Dubois-Laforgue D, Donadille B, Ciangura C, et al.
Orphanet journal of rare diseases 2026; (17(Suppl 1)).
PMID: 42227416
This page is for informational purposes only and does not constitute medical advice about FRTS4 with HNF4A-MODY. Your nephrologist, endocrinologist, and genetics professional can help interpret your results and plan care.